Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility.
about
Historical data analyses and scientific knowledge suggest complete removal of the abnormal toxicity test as a quality control testStrategies and Methodologies for Developing Microbial Detoxification Systems to Mitigate MycotoxinsStability of benzocaine formulated in commercial oral disintegrating tablet platforms.Compatibility study of paracetamol, chlorpheniramine maleate and phenylephrine hydrochloride in physical mixtures.Impact of excipient interactions on solid dosage form stability.Why is mannitol becoming more and more popular as a pharmaceutical excipient in solid dosage forms?Oxidation of therapeutic proteins and peptides: structural and biological consequences.Mechanism of Decarboxylation of Pyruvic Acid in the Presence of Hydrogen PeroxideSurface acidity and solid-state compatibility of excipients with an acid-sensitive API: case study of atorvastatin calciumRecent trends in product development and regulatory issues on impurities in active pharmaceutical ingredient (API) and drug products. Part 1: Predicting degradation related impurities and impurity considerations for pharmaceutical dosage forms.'APAAN in the neck' - A reflection on some novel impurities found in seized materials containing amphetamine in Ireland during routine forensic analysis.Effect of the Wetting Agent Sodium Lauryl Sulfate on the Pharmacokinetics of Alectinib: Results From a Bioequivalence Study in Healthy Subjects.Use of к-carrageenan, chitosan and Carbopol 974P in extruded and spheronized pellets that are devoid of MCC.
P2860
Q26825211-79336283-7B58-4568-8998-97A7AB54A0F5Q33612034-CA9CBF4C-3B3F-44A4-854D-CDD3530CD14CQ37343514-F8545F8B-6321-4A7F-B0C3-758FC3A64A0BQ37643103-AF82E543-890A-4EB3-9814-62511D4A0002Q38019469-6DFA95A1-5D97-4A1D-837D-8EE80A02CB9AQ38092913-BF62F8BA-0BB8-48F9-B65F-2DCBD3539D92Q38142887-345023EC-84E4-46C6-9C80-EDCBEFD3EC87Q39698294-3EB784FD-A609-4C69-9680-FBF7A40DAAACQ41843059-7594647E-B61A-4C29-8F1E-29107C3C30B9Q41904441-CDA08B4F-B9D0-4899-BFBA-C8B0B72D83E3Q48088901-70265756-7A9A-47F8-8AAD-3D5F6153AA01Q51280223-7ACE311D-2CF2-4F8C-B6DF-CB8CD2AA3701Q51362751-49E6A08E-241E-4723-9D6D-D33BE7FABD18
P2860
Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Reactive impurities in excipie ...... rug-excipient incompatibility.
@en
Reactive impurities in excipie ...... rug-excipient incompatibility.
@nl
type
label
Reactive impurities in excipie ...... rug-excipient incompatibility.
@en
Reactive impurities in excipie ...... rug-excipient incompatibility.
@nl
prefLabel
Reactive impurities in excipie ...... rug-excipient incompatibility.
@en
Reactive impurities in excipie ...... rug-excipient incompatibility.
@nl
P2093
P2860
P1433
P1476
Reactive impurities in excipie ...... rug-excipient incompatibility.
@en
P2093
Ajit S Narang
Jaquan Levons
Krishnaswamy Raghavan
Venkatramana M Rao
Yongmei Wu
P2860
P2888
P304
P356
10.1208/S12249-011-9677-Z
P407
P577
2011-09-27T00:00:00Z
P5875
P6179
1016644007